openPR Logo
Press release

Recent Study on Ovarian Cancer Identifying and Commercializing First-in-Class Innovation | Researchmoz.us

04-03-2017 03:47 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Ovarian Cancer

Researchmoz added Most up-to-date research on "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.

Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is generally considered an effective treatment for localized tumors, however the management of recurrent and later-stage disease is largely reliant on cytotoxic chemotherapy regimens.

A highly active ovarian cancer pipeline contains an array of diverse molecule types and molecular targets, in contrast to the market. With the diversity in the pipeline, there is hope that innovative products can make it to market to provide patients with greater therapeutic options, while meeting unmet needs within ovarian cancer. There are 179 ovarian cancer pipeline products associated with a first-in-class molecular target representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. Such a diverse and innovative pipeline implies that approaches to ovarian cancer treatment are changing and first-in-class development is playing a significant role in this.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=499491

Scope

Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset.

- What survival benefits do current therapies provide?
- What are the current unmet needs that the pipeline needs to address?
- The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
- What potential do mAbs have in ovarian cancer treatment?
- Will pipeline diversity translate to clinically and commercially successful therapies?
- How are common target families, such as intracellular signal transduction associated with pathophysiology?
- 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.
- Do first-in-class products show strong progression into the later stages?
- Why is the greatest number of first-in-class products seen in signal transduction?
- First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways
- How well are first-in-class targets, such as Notch, aligned to known disease causing pathways?
- Which targets are specifically found in early-stage development?
- What is the industry-wide interest in these targets?
- Co-development deals for first-in-class products are typically higher value than non-first-in-class counterparts.
- To what extent does first-in-class status influence deal value and phase?
- Can biologics command a greater deal value than other molecule types?

Reasons to buy

This report will allow you to
- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the ovarian cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the ovarian cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating ovarian cancer.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify commercial opportunities in the ovarian cancer deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of ovarian cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=499491

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recent Study on Ovarian Cancer Identifying and Commercializing First-in-Class Innovation | Researchmoz.us here

News-ID: 489861 • Views: 245

More Releases from Ovarian Cancer

Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Fron …
Researchmoz added Most up-to-date research on "Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma" to its huge collection of research reports. Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is
Ovarian Cancer - US Market Insights, Epidemiology and Market Forecast-2020
ALBANY, NY, April 6, 2017 : DelveInsights Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer from 2012-2020. According to DelveInsight, the forecasted patient population of Ovarian cancer will decrease at a CAGR
Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017
Researchmoz added Most up-to-date research on "Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017" to its huge collection of research reports. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells
Global Historical And Forecasted Epidemiological Data For Diagnosed Incident Cas …
ResearchMoz presents this most up-to-date research on "Global Historical And Forecasted Epidemiological Data For Diagnosed Incident Cases Of Ovarian Cancer From 2017 - 2020". DelveInsights Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer

All 5 Releases


More Releases for Identify

N95 Disposable Mask Market: Identify Hidden Opportunities
The latest research report on Global N95 Disposable Mask examines investment in Market. It describes how companies deploying these technologies across various industry verticals aim to explore its potential to become a major business disrupter. The study eludes very useful reviews & strategic assessment including the generic market trends, emerging technologies, industry drivers, challenges, regulatory policies that propel the market growth, along with major players profile and strategies. This version
Wellving Asset Management Identify IPO
Not a company to rest on their laurels Wellving Asset Management have identified what could be the next investment vehicle for their clients. It comes in the form of an IPO. IPO stands for initial Public Offering. In other words, it is a new issue of stock offered for sale to the public. When companies first start out, the shares are held privately. At some point, a majority of the owners
Identify Hidden Opportunities of Parcel Delivery Market
A latest survey on Global Parcel Delivery Market is conducted covering various organizations of the industry from different geographies to come up with 100+ page report. The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition is facing along with gap analysis and new opportunity available and may trend in Parcel Delivery market. The report bridges the historical data from
Identify Hidden Opportunities of Banking BPS Market
A new market study on Global Banking BPS Market with 100+ market data Tables, Pie Chart & Graphs is released that will provide complete assessment of the Market and covers evolving trends, current scenario analysis and growth factors, and industry validated market data. The research study provides market breakdown by revenue and volume (if applicable) and price history estimates for Global Banking BPS. Some are the key players from the
Identify Hidden Opportunities of Cancer Insurance Market
A latest survey on Southeast Asia Cancer Insurance Market is conducted covering various organizations of the industry from different geographies to come up with 100+ page report. The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition is facing along with gap analysis and new opportunity available and may trend in Southeast Asia Cancer Insurance market. The report bridges the
Identify Hidden Opportunities of, E-Sports Market
A latest survey on Global E-Sports Market is conducted covering various organizations of the industry from different geographies to come up with 100+ page report. The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition is facing along with gap analysis and new opportunity available and may trend in E-Sports market. The report bridges the historical data from 2013 to